References
- Beal MF, Shults CW. Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors 2003; 18: 153–161
- Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res 1998; 68: 109–113
- Cooper JM, Schapira AH. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy. Biofactors 2003; 18: 163–171
- Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001; 20: 591–598
- Erhardt JG, Mack H, Sobeck U, Biesalski HK. Carotene and β-tocopherol concentration and antioxidant status in buccal mucosal cells and plasma after oral supplementation. Br J Nutr 2002; 87: 471–475
- Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33: 226–229
- Jeanes YM, Hall WL, Ellard S, Lee E, Lodge JK. The absorption of vitamin E is influenced by the amount of fat in a meal and the food matrix. Br J Nutr 2004; 92: 575–579
- Joshi SS, Sawant SV, Shedge A, Halpner AD. Comparative bioavailability of two novel coenzyme Q10 preparations in humans. Int J Clin Pharmacol Ther 2003; 41: 42–48
- Kurowska EM, Dresser G, Deutsch L, Bassoo E, Freeman DJ. Relative bioavailability and antioxidant potential of two coenzyme q10 preparations. Ann Nutr Metab 2003; 47: 16–21
- Leonard SW, Good CK, Gugger ET, Traber MG. Vitamin E bioavailability from fortified breakfast cereal is greater than that from encapsulated supplements. Am J Clin Nutr 2004; 79: 86–92
- Lu WL, Zhang Q, Lee HS, Zhou TY, Sun HD, Zhang DW, Zheng L, Lee M, Wong SM. Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets. Biol Pharm Bull 2003; 26: 52–55
- Lyon W, Van den BO, Pepe S, Wowk M, Marasco S, Rosenfeldt FL. Similar therapeutic serum levels attained with emulsified and oil-based preparations of coenzyme Q10. Asia Pac J Clin Nutr 2001; 10: 212–215
- Miles MV, Horn P, Miles L, Tang P, Steele P, DeGrauw T. Bioequivalence of coenzyme Q10 from over-the-counter supplements. Nutr Res 2002; 22: 919–929
- Molyneux S, Florkowski C, Lever M, George P. The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly. N Z Med J 2004; 117: U1108
- Mosca F, Fattorini D, Bompadre S, Littarru GP. Assay of coenzyme Q(10) in plasma by a single dilution step. Anal Biochem 2002; 305: 49–54
- Natarajan N, Shambaugh KME, Haines GK, Radosevich JA. Adaptation of the diphenylamine (DPA) assay to a 96-well plate tissue culture format and comparison with the MTT assay. BioTechniques 1994; 17: 166–171
- Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 1996; 13: 528–534
- Niklowitz P, Menke T, Andler W, Okun JG. Simultaneous analysis of coenzyme Q10 in plasma, erythrocytes and platelets: comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults. Clin Chim Acta 2004; 342: 219–226
- Peng YM, Peng YS, Lin Y, Moon T, Roe DJ, Ritenbaugh C. Concentrations and plasma-tissue-diet relationships of carotenoids, retinoids, and tocopherols in humans. Nutr Cancer 1995; 23: 233–246
- Roffe L, Schmidt K, Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol 2004; 22: 4418–4424
- Seeballuck F, Lawless E, Ashford MB, O'Driscoll CM. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm Res 2004; 21: 2320–2326
- Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59: 1541–1550
- Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol. Biofactors 2003; 18: 125–127
- Tang PH, Miles MV, Steele P, DeGrauw A, Chuck G, Schroer L, Pesce A. Anticoagulant effects on plasma coenzyme Q(10) estimated by HPLC with coulometric detection. Clin Chim Acta 2002; 318: 127–131
- Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther Toxicol 1986; 24: 536–541
- Ullmann U, Metzner J, Schulz C, Perkins J, Leuenberger B. A new Coenzyme Q10 tablet-grade formulation (all-Q) is bioequivalent to Q-Gel and both have better bioavailability properties than Q-SorB. J Med Food 2005; 8: 397–399
- Weber C, Bysted A, Holmer G. Coenzyme Q10 in the diet—daily intake and relative bioavailability. Mol Aspects Med 1997; 18(Suppl)S251–S254
- Weis M, Mortensen SA, Rassing MR, Moller-Sonnergaard J, Poulsen G, Rasmussen SN. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994; 15(Suppl)s273–s280